NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt turns negative
Q1 FY2026 net debt was -$5.78M, compared with $2.85M a year earlier.
Context
- Net debt amounted to 48.6% of total assets at the end of Q1 FY2026, up 11.0 pp from a year earlier.
- Net debt increased in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -302.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (7.17M) USD
- Year-over-year change
- -239.6%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.17M) | -239.6% |
| FY2024 | 2024-12-31 | 5.13M | +12.4% |
| FY2023 | 2023-12-31 | 4.57M | +147.9% |
| FY2022 | 2022-12-31 | (9.53M) | +64.8% |
| FY2021 | 2021-12-31 | (27.09M) | — |
Net Debt vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 net debt of -$5.78M is the 5th highest of the 9 companies compared; the peer median is -$9.03M.
- Its year-over-year change of -302.8% is the 7th highest of 9, against a peer median of -108.3%.
- Net debt amounts to 48.6% of total assets for NRXP, versus a peer median of 86.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $140.02M | -5.3% | +58.0% | 106.5% | |
| Mar 2026 | $19.44M | -24.5% | — | 88.8% | |
| Mar 2026 | -$3.02M | -473.2% | — | 0.9% | |
| Mar 2026 | -$5.11M | -129.4% | — | 25.8% | |
| Mar 2026 | -$5.78M | -302.8% | — | 48.6% | |
| Mar 2026 | -$12.94M | -115.3% | — | 41.9% | |
| Jun 2026 | -$21.99M | +45.6% | — | 91.0% | |
| Mar 2026 | -$46.96M | -101.4% | — | 83.6% | |
| Mar 2026 | -$60.63M | -326.8% | — | 96.1% | |
| Peer median (excluding NRXP) | -$9.03M | -108.3% | +58.0% | 86.2% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.